Quantinno Capital Management LP Grows Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Quantinno Capital Management LP raised its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 34.5% during the third quarter, HoldingsChannel reports. The firm owned 36,145 shares of the company’s stock after purchasing an additional 9,269 shares during the period. Quantinno Capital Management LP’s holdings in Teva Pharmaceutical Industries were worth $651,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of TEVA. Sequoia Financial Advisors LLC boosted its position in Teva Pharmaceutical Industries by 0.7% during the third quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company’s stock valued at $2,025,000 after purchasing an additional 805 shares in the last quarter. Smithfield Trust Co lifted its position in shares of Teva Pharmaceutical Industries by 55.7% during the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after buying an additional 980 shares during the last quarter. Signaturefd LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 16.9% in the 3rd quarter. Signaturefd LLC now owns 7,583 shares of the company’s stock valued at $137,000 after buying an additional 1,094 shares in the last quarter. Bridgewater Associates LP boosted its stake in Teva Pharmaceutical Industries by 5.2% in the third quarter. Bridgewater Associates LP now owns 23,222 shares of the company’s stock valued at $418,000 after acquiring an additional 1,144 shares in the last quarter. Finally, United Services Automobile Association grew its holdings in Teva Pharmaceutical Industries by 3.1% in the second quarter. United Services Automobile Association now owns 41,159 shares of the company’s stock worth $669,000 after purchasing an additional 1,249 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Insider Activity at Teva Pharmaceutical Industries

In related news, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the sale, the executive vice president now owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.55% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts recently issued reports on TEVA shares. JPMorgan Chase & Co. upped their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st. UBS Group increased their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Barclays boosted their target price on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. Finally, StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $19.67.

Teva Pharmaceutical Industries Stock Down 1.8 %

TEVA opened at $16.50 on Friday. The company has a fifty day moving average of $17.49 and a two-hundred day moving average of $17.39. The stock has a market capitalization of $18.69 billion, a price-to-earnings ratio of -19.41, a PEG ratio of 1.04 and a beta of 0.79. Teva Pharmaceutical Industries Limited has a fifty-two week low of $9.90 and a fifty-two week high of $19.31. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.